CAS 73631-58-0 | 4-(2-Aminoethyl)benzenesulfonic acid>99.0%

4-(2-Aminoethyl)benzenesulfonic acid
Purity: ≥99.0%
Synonyms: 4-(2-Aminoethyl)benzenesulfonic acid, 4-AEPSA
CAS number: 73631-58-0
Molecular formula: C8H11NO3S
Molecular weight: 201.24

FLUORESCENT LABELING AGENT AND FLUORESCENT DYE

Current Patent Assignee: TOYO INK SC HOLDINGS COMPANY LIMITED - US2023/145826, 2023, A1

Patent Family Members: CN115335489 A; EP4130163 A1; JPWO2021/201284 A1; US2023/145826 A1; WO2021/201284 A1

Abstract

A fluorescent labeling agent contains a fluorescent dye represented by general formula (1). General formula (1): Q-Z—R1-R2-R3 (In the formula, Q represents the residue of a fluorescent dye. Z represents a direct bond, alkylene group, or arylene group. R1 represents a direct bond, —O—, —OP(═O)R4—, —OC(═O)—, —OS(═O)2—, —OSiR5R6—, —C(═O)—, or —C(═O)NH—. R2 represents a group selected from the group consisting of alkylene groups, arylene groups, and heterocyclic groups, or represents a group provided by combining these groups. R3 represents —COOM1, —NR7R8, or —N+R9R10R11. Here, R4 represents a hydrogen atom, hydroxyl group, alkyl group, aryl group, alkoxy group, aryloxy group, or heterocyclic group. R5 and R6 each independently represent an alkyl group, aryl group, or heterocyclic group. R7-R11 each independently represent a hydrogen atom, alkyl group, or aryl group. M1 represents a monovalent cation.)

AMPK activators

Current Patent Assignee: KALLYOPE INC - US11407768, 2022, B2

Patent Family Members: US11407768 B2; US2022/2317 A1; WO2021/263039 A1; US2022/340599 A1; AU2021297323 A1; ...

Abstract

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.